Get Your Personalized Supplement StackSupplement Stack Quiz

Cyplexinol

Also known as: Cyplexinol, hydrolyzed collagen with BMPs, hydrolyzed bovine collagen enriched with bone morphogenetic proteins

Overview

Cyplexinol® is a proprietary nutritional supplement derived from hydrolyzed bovine bone collagen, specifically enriched with bioactive bone morphogenetic proteins (BMPs), including BMP-2, BMP-4, and BMP-7. These BMPs are signaling proteins naturally involved in bone and cartilage metabolism. Marketed primarily for alleviating joint pain and improving joint function, Cyplexinol is often used by individuals experiencing osteoarthritis and chronic joint discomfort. It is administered orally as a dietary supplement, aiming to stimulate cartilage repair and bone remodeling. While research is emerging, initial clinical evidence, including randomized controlled trials, suggests potential benefits. However, the quality of evidence is still developing, with limited large-scale, independent studies, and the oral bioavailability of intact BMPs remains a subject of ongoing discussion.

Benefits

Cyplexinol has shown promising primary effects in reducing joint pain and stiffness. Clinical trials, particularly one placebo-controlled RCT, reported significant improvements in WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) and VAS (Visual Analog Scale) scores within just two weeks of supplementation in middle-aged adults with chronic joint pain. These improvements were statistically significant, though modest in magnitude. Secondary benefits include increased serum levels of BMP-5 and TGF-β, suggesting potential anabolic effects on cartilage and bone metabolism. These biochemical changes indicate a possible role in enhancing endogenous repair processes within joints. The benefits have been observed specifically in middle-aged men and women experiencing knee and/or hip joint pain, with effects appearing rapidly, often within 15 days of daily supplementation. However, data on other populations or long-term effects are currently unavailable.

How it works

Cyplexinol's mechanism of action centers on its bone morphogenetic protein (BMP) content. BMPs are growth factors crucial for regulating bone and cartilage formation by stimulating chondrocyte proliferation and extracellular matrix synthesis. By delivering these BMPs orally, Cyplexinol aims to enhance the body's natural repair processes within joints. It primarily targets the musculoskeletal system, specifically influencing cartilage and bone tissue remodeling. At a molecular level, BMPs interact with BMP receptors on chondrocytes (cartilage cells) and osteoblasts (bone-forming cells), and also influence TGF-β signaling pathways. While hydrolyzed collagen peptides are generally absorbed, the oral bioavailability of intact BMP proteins is not yet well-established, raising questions about the direct delivery mechanism of these specific signaling proteins.

Side effects

Based on available randomized controlled trials, Cyplexinol appears to have a favorable safety profile for short-term use (up to two weeks), with no serious adverse events reported. Common side effects were not reported at a frequency greater than 5% in the studies. Due to the limited duration and scope of current research, uncommon or rare side effects have not been identified. There are no documented drug interactions, but caution is advised due to the limited data. Standard precautions applicable to collagen supplements generally apply, as specific contraindications for Cyplexinol have not been established. Furthermore, there is no safety data available for special populations such as pregnant or lactating women, children, or individuals with severe comorbidities, necessitating caution in these groups.

Dosage

The minimum effective dose for Cyplexinol has not been explicitly defined, as clinical trials utilized proprietary formulations consistent with product labeling, without specifying exact milligram dosages in the provided sources. However, clinical studies indicate that daily supplementation for at least 15 days showed observable benefits. An optimal dosage is not yet established, nor is a maximum safe dose. Cyplexinol is typically administered daily via oral consumption, though the timing relative to meals is not specified. It is available as a hydrolyzed collagen powder or in capsule form, standardized for its BMP content. While hydrolyzed collagen peptides are generally absorbed, the absorption and stability of intact BMPs orally require further investigation. No specific cofactors have been reported as necessary for its efficacy.

FAQs

Is Cyplexinol effective for joint pain?

Evidence from one placebo-controlled randomized controlled trial suggests modest reductions in joint pain and stiffness over two weeks in middle-aged adults with chronic joint pain.

Is Cyplexinol safe to use?

Short-term use (up to two weeks) appears safe, with no significant adverse events reported in the available clinical trials.

How quickly can I expect to see results from Cyplexinol?

Benefits have been observed relatively quickly, with improvements in joint pain and stiffness noted within 15 days of daily supplementation.

Does Cyplexinol regenerate cartilage?

While Cyplexinol has been shown to increase levels of BMP and TGF-β, which are associated with anabolic effects on cartilage, direct evidence of cartilage regeneration in humans is currently lacking.

Can the bone morphogenetic proteins (BMPs) in Cyplexinol be absorbed orally?

The oral bioavailability of intact BMPs is a subject of ongoing scientific debate and is not yet definitively established, requiring further research.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC10339409/ – This randomized, placebo-controlled trial investigated Cyplexinol's effects on joint pain and biochemical markers over 15 days in middle-aged adults. It found significant improvements in WOMAC and VAS pain scores, alongside increased BMP-5 and TGF-β levels, with no reported adverse events. The study, while well-designed, had a short duration and moderate sample size, with partial manufacturer funding.
https://accscience.com/journal/JCTR/9/3/10.18053/jctres.09.202303.003 – This placebo-controlled RCT, similar to the first, confirmed improvements in pain and stiffness and elevated biochemical markers (BMP-5, TGF-β) over two weeks. It noted no cytokine modulation and had an adequate design, but was limited by its short-term nature and sample size, lacking long-term follow-up or independent replication.
https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.1026450/full – This systematic review and meta-analysis focused on the role of antioxidants in knee osteoarthritis. While a high-quality meta-analysis, it does not directly address Cyplexinol or its specific mechanisms, making its relevance to Cyplexinol's direct effects indirect and limited.
https://regenexx.com/blog/cyplexinol-review-2-more-of-the-bmp-shuffle/ – This source provides a critical review of Cyplexinol, specifically questioning the oral bioavailability of BMPs and the direct delivery mechanism. It highlights the ongoing debate and lack of robust evidence regarding whether intact BMPs can be effectively absorbed and utilized when taken orally.